Exploring the Benefits of SGLT2 Inhibitors in Chronic Kidney Disease

Published on: 
, ,

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP:-BC, interview Dr Robert Busch, to explore the advantages of SGLT2 inhibitors in chronic kidney disease, cardiovascular health, and their potential to improve overall patient outcomes.

To watch the video series component of this episode, click here.

1:21 Treatment landscape for CKD

3:42 Prevalence of CKD in people with diabetes

5:25 Mechanism of SGLT2 inhibitors

8:05 Benefits of SGLT2 inhibitors in non-diabetic patients

9:02 Cardiovascular benefits of SGLT2 inhibitors

11:24 Comparative efficacy of SGLT1,2 inhibitors

13:54 Impact of SGLT2 inhibitors on diabetes

16:50 Adverse effects of SGLT2 inhibitors

20:30 Effect of SGLT2 inhibitors in euglycemic DKA

23:08 Combining SGLT2 inhibitors with other diabetes medications

28:14 Combining finerenone with SGLT2 inhibitors